Bloomberg

Biogen's Japanese partner has second Alzheimer's drug coming

Foto: Tim Gruber

Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer's disease to the U.S market. Investors are hoping Eisai Co. Ltd, its Japanese partner in the medicine, can do it again with a second compound from the pair that's still in development.

The U.S. Food and Drug Administration's backing of the drug Aduhelm may boost the chances for BAN2401 and Tokyo-based Eisai, which is in a sales and profit sharing agreement with Biogen for both treatments. The drugs work by targeting the beta amyloid protein that clogs the brains of patients with Alzheimer's disease...

BRANCHENYT
Læs også